CompletedPhase 2

Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis

Italy560 participantsStarted 2018-03-26

Plain-language summary

The objective of the study is to demonstrate the superiority of the mesoglycan (Prisma®), compared to placebo, in reducing the incidence of thromboembolic complications (relapse / extension of superficial venous thrombosis (SVT), deep venous thrombosis (DVT), pulmonary embolism (PE)) in patients who have completed the cycle of therapy of the acute phase after superficial vein thrombosis.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subjects of both genders, aged\> = 18 years,
✓. With previous diagnosis of SVT of the lower limbs documented by color-coded duplex ultrasonography (CCDU), which at the onset was at least 5 cm of extension and at least 3 cm from the saphenous junctions (vena magna saphenous and saphenous),
✓. who have completed the initial therapeutic cycle with Fondaparinux 2.5 mg / day for 45 days, as required by the most recent Guidelines (ACCP).
✓. That screening CCDU does not show deep venous involvement, or an extension of the initial SVT.

Exclusion criteria

✕. Poor compliance with the treatment of SVT,
✕. life expectancy \<24 months,
✕. anticipated lack of cooperation or impossibility to complete the questionnaires,
✕. pregnancy, lactation or programmed pregnancy during the duration of the study,
✕. severe locomotor disability or prolonged immobilization,
✕. participation in another study in the last 3 months,
✕. post-thrombotic syndrome with "Villalta score"\> 4,
✕. chronic lymphedema of the lower limbs,

What they're measuring

Cumulative thrombosis recurrence

Timeframe: 12 months

Trial details

NCT IDNCT03428711

SponsorQuovadis Associazione

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-31

View on ClinicalTrials.gov More Superficial Venous Thrombosis of Leg, Secondary Prevention trials